LIMR was instrumental in bringing the following therapeutics to patient care:
Indoximod is a small molecule drug in late-stage clinical development that targets the IDO pathway with a distinct mechanism of action. The drug was developed in a collaboration between NewLink Genetics Corp. and LIMR.
Incubated at LIMR, Synovasure by CD Diagnostics is an FDA-authorized product that tests patients’ synovial fluid for periprosthetic joint infection (PJI), most often seen in knee and hip replacements. Developed by Carl Deirmengian, MD, an orthopaedic surgeon at Main Line Health and a clinical assistant professor at LIMR, Synovasure tests for a peptide released by neutrophils. The test has sensitivity and specificity rates that are markedly better than other available tests. CD Diagnostics is now a subsidiary of Zimmer Biomet.
Learn more about Synovasure® in the Spring 2017 issue of Catalyst
MyNauseaRisk test is LIMR's blood-based assay that reliably predicts which cancer patients will experience delayed-onset nausea after chemotherapy, even before the chemotherapy is administered.
Learn more about MyNauseaRisk in the spring/summer 2018 edition of Catalyst
LIMR’s TIMP-4 test determines if small triple-negative breast cancers are aggressive, and therefore are best treated with chemotherapy.